scholarly article | Q13442814 |
P50 | author | Pavel Dráber | Q102053371 |
Christos D Katsetos | Q117803393 | ||
P433 | issue | 19 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2778-92 | |
P577 | publication date | 2012-01-01 | |
P1433 | published in | Current Pharmaceutical Design | Q5195068 |
P1476 | title | Tubulins as therapeutic targets in cancer: from bench to bedside | |
P478 | volume | 18 |
Q64892794 | A Survey on Tubulin and Arginine Methyltransferase Families Sheds Light on P. lividus Embryo as Model System for Antiproliferative Drug Development. |
Q61453755 | Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action |
Q58547427 | Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives |
Q36562191 | Bis-cyclopropane analog of disorazole C1 is a microtubule-destabilizing agent active in ABCB1-overexpressing human colon cancer cells |
Q38404084 | Class III β-tubulin in normal and cancer tissues |
Q34155176 | Computational identification of surrogate genes for prostate cancer phases using machine learning and molecular network analysis |
Q38015371 | Cytoskeleton in mast cell signaling |
Q37447324 | Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. |
Q27005747 | Epothilones: From discovery to clinical trials |
Q38954268 | Hypoxia-inducible factor-2α (HIF-2α), but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells |
Q89932847 | Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action |
Q34313834 | Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. |
Q38816570 | MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation |
Q38984991 | Microtubule Destabilization Paves the Way to Parkinson's Disease. |
Q38726651 | Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer. |
Q38863581 | Overexpression and Nucleolar Localization of γ-Tubulin Small Complex Proteins GCP2 and GCP3 in Glioblastoma |
Q49849048 | Radiosynthesis and in vivo evaluation of [11C]MPC-6827, the first brain penetrant microtubule PET ligand. |
Q64974153 | Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents. |
Q38852408 | Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway |
Q64097833 | Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types |
Q90163186 | Synthesis and Antiproliferative Screening Of Novel Analogs of Regioselectively Demethylated Colchicine and Thiocolchicine |
Q59794796 | Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting Anticancer Agents |
Q38092648 | The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics |
Q89966987 | Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle |
Q38933291 | Use of Integrated Computational Approaches in the Search for New Therapeutic Agents |
Q28284878 | βIII-Tubulin: biomarker of taxane resistance or drug target? |
Search more.